Resumo

MASSON, WALTER  e  GIORGI, MARIANO. Efficacy, Safety and Clinical Applicability of PCSK9 Inhibitors. Rev. argent. cardiol. [online]. 2020, vol.88, n.2, pp.153-163. ISSN 1850-3748.  http://dx.doi.org/10.7775/rac.es.v88.i2.17470.

Proprotein convertase subtilisin kexin type 9 (iPCSK9) inhibitors represent a new group of lipid-lowering drugs that have generated a substantial change in lipid management. In a few years, a large number of studies have evaluated the lipid efficacy and safety of these drugs. More recently, large randomized clinical trials showed that the decrease in LDL-C achieved with these drugs was associated with a lower incidence of cardiovascular events. Such evidence resulted in the approval and commercialization of iPCSK9 in many countries. Consequently, various scientific societies and health reference agencies incorporated these drugs into the therapeutic arsenal of dyslipidemia, with the aim of reducing residual cardiovascular risk. In this review, we will describe the efficacy and safety of these drugs, analyze the available evidence about cardiovascular benefit, and discuss in which population their use might be most effective.

Palavras-chave : Dyslipidemia; Drug treatment; PCSK9 inhibitors.

        · resumo em Espanhol     · texto em Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )